Authorized purpose: CS-series-FP radiographic and fluoroscopic systems support cardiac, vascular, general, and interventional procedures; FluoroShield provides secondary region-of-interest collimation with lower-refresh peripheral context.
Clinical role
Image reconstruction, localization, navigation, or procedural guidance under direct professional control.
Images and patients
Fluoroscopy/Angiography · Multi-region
Key limitation
Keep in mind: At no time will the CA-100S/FluoroShield be considered as a replacement for the primary collimator. The primary collimator shall always be used, in accordance with good medical practice, to define a ROI.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CS-series-FP radiographic and fluoroscopic systems support cardiac, vascular, general, and interventional procedures; FluoroShield provides secondary region-of-interest collimation with lower-refresh peripheral context.
Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Multi-region Input: Radiographic/fluoroscopic diagnostic and interventional X-ray imaging.
Who uses it?Intended users: Physician or operator.
What does the software produce?Output: The CA-100S ROI image processing combines the live ROI with the legacy image of the full field of view (defined by the primary collimator).
What is its most important limitation?Key limitation: At no time will the CA-100S/FluoroShield be considered as a replacement for the primary collimator. The primary collimator shall always be used, in accordance with good medical practice, to define a ROI.
Clinical takeaway. Clinical role: CS-series-FP radiographic and fluoroscopic systems support cardiac, vascular, general, and interventional procedures; FluoroShield provides secondary region-of-interest collimation with lower-refresh peripheral context.
Evidence takeaway. Evidence from the reviewed source record: K191713 reports bench dose-area-product testing and a third-party clinical evaluation supporting the region-of-interest collimation workflow.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CS-series-FP radiographic and fluoroscopic systems support cardiac, vascular, general, and interventional procedures; FluoroShield provides secondary region-of-interest collimation with lower-refresh peripheral context.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The CA-100S ROI image processing combines the live ROI with the legacy image of the full field of view (defined by the primary collimator).
Exact FDA submission
Checked 2026-09-19
The packet directly describes the blended ROI/full-field image output rather than the dossier's generic landmarks, measurements, overlays, or navigation guidance.
At no time will the CA-100S/FluoroShield be considered as a replacement for the primary collimator. The primary collimator shall always be used, in accordance with good medical practice, to define a ROI.
Exact FDA submission
Checked 2026-09-19
This is the packet's direct collimator limitation; the dossier's local-practice dose disclaimer is not stated.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K191713 reports bench dose-area-product testing and a third-party clinical evaluation supporting the region-of-interest collimation workflow.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K191713 FDA performance package for CS-series-FP Radiographic / Fluoroscopic Systems with Optional CA-100S / FluoroShield™ (ROI Assembly)
DesignManufacturer bench dosimetry plus third-party clinical workflow evaluation
PopulationSupported cardiac, vascular, general, and interventional fluoroscopy procedures
Scopeexact submission
Tested versionCS-series-FP with CA-100S and FluoroShield
IndependenceSponsor or vendor study
K191713
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K191713 by exact submission identifier. This does not exclude product-family or later safety information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Radiographic/fluoroscopic diagnostic and interventional X-ray imaging.
Scope: Exact FDA submission. The packet's stated imaging scope is radiographic/fluoroscopic X-ray imaging, not the dossier's multi-modality input set.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Procedure-room hardware and software or a connected workstation with supported imaging equipment and accessories.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: The CA-100S ROI image processing combines the live ROI with the legacy image of the full field of view (defined by the primary collimator).
Scope: Exact FDA submission. The packet directly describes the blended ROI/full-field image output rather than the dossier's generic landmarks, measurements, overlays, or navigation guidance.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The CA-100S ROI image processing combines the live ROI with the legacy image of the full field of view (defined by the primary collimator).
Scope: Exact FDA submission. The packet directly describes the blended ROI/full-field image output rather than the dossier's generic landmarks, measurements, overlays, or navigation guidance.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Only qualified physicians, technologists, or procedural staff trained for the specified intervention. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The primary collimator remains required. Dose-area-product and image-quality findings are configuration- and procedure-specific and do not guarantee dose reduction in local practice.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The primary collimator remains required. Dose-area-product and image-quality findings are configuration- and procedure-specific and do not guarantee dose reduction in local practice.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The primary collimator remains required. Dose-area-product and image-quality findings are configuration- and procedure-specific and do not guarantee dose reduction in local practice.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The indications statement uses radiographic/fluoroscopic applications and does not state the dossier's angiography label. Controlled directory display reconciled from exact FDA wording: Radiographic/fluoroscopic applications. -> Fluoroscopy/Angiography.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
13Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 13 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 13 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-03 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: LUMINOS Q.namix T and LUMINOS Q.namix R are multifunctional radiography and fluoroscopy systems for routine radiography and fluoroscopic examinations including gastrointestinal, urogenital, arthrographic, angiographic, and pediatric workflows; they are not mammography systems.
Authorized purpose: 3DXR reconstructs cone-beam CT from interventional X-ray acquisitions and uses CleaRecon DL to reduce streak artifacts for display in the advanced workstation workflow.
Authorized purpose: EndoNaut fuses planning images with live fluoroscopy and provides computerized navigation support for fluoroscopy-guided aneurysm repair, embolization, and peripheral-artery procedures involving the chest, abdomen, pelvis, neck, or lower limbs.
EndoNaut overlays preoperative three-dimensional vascular anatomy on live fluoroscopy and supports semi-automatic registration and motion detection for selected aneurysm, angioplasty, stenting, and embolization procedures.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.